Both of them are pivotal players in the inflammatory response and autoimmune diseases (Jang et al., 2021; Liu et al., 2022; Zhang et al., 2022), exerting disruptive effects on epithelial tissue barrier function by inhibiting the synthesis of tight junction proteins and cadherins (Rochfort and Cummins, 2015; Ng et al., 2018; Rahman et al., 2018). Here, CDH17 is linked to autoimmune disease.